You are using an outdated browser. Please upgrade your browser to improve your experience and security.

The first dual-drug liposomal encapsulation of daunorubicin and cytarabine shown to...

Deliver superior overall survival vs 7+3a to adults with newly-diagnosed secondary AML (t-AML or AML-MRC)1

Explore clinical data

Median overall survival was 9.6 months for VYXEOS vs 5.9 months for 7+3 (P=0.005; HR=0.69 [0.52, 0.90]) in a Phase 3 trial.1

Phase 3 randomized, multicenter, open-label, active-controlled study of VYXEOS vs cytarabine and daunorubicin (7+3) in patients 60 to 75 years of age with newly-diagnosed t-AML or AML-MRC.1 See full study design

Husband and wife at garden center inside VYXEOS (daunorubicin and cytarabine) liposome

The only dual-drug liposomal encapsulation of daunorubicin and cytarabine for adults with newly-diagnosed secondary AML (t-AML or AML-MRC)

VYXEOS was shown to deliver superior overall survival vs 7+31,a

Secondary AML subtypes

Identifying and diagnosing t-AML and AML-MRC

Learn more

Video library

Featuring healthcare professionals and patients talking about VYXEOS

Watch now

Median overall survival was 9.6 months for VYXEOS vs 5.9 months for 7+3 (P=0.005; HR=0.69 [0.52, 0.90]) in a Phase 3 trial.1

Phase 3 randomized, multicenter, open-label, active-controlled study of VYXEOS vs cytarabine and daunorubicin (7+3) in patients 60 to 75 years of age with newly-diagnosed t-AML or AML-MRC.1 See full study design

checkmark icon

CMS approves new technology add-on payment (NTAP) for VYXEOS

VYXEOS meets the definition of newness, substantial clinical improvement relative to existing therapies, and cost thresholds. Contact your Jazz Access and Reimbursement Manager (ARM) for more information.

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.